MedTrace Logo

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2013-02-08

No results posted yet for this study

Summary

The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.

Conditions

  • Kidney Transplant

Interventions

DRUG

sirolimus

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Canada
  • Chile
  • Cyprus
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Norway
  • Portugal
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00137345 on ClinicalTrials.gov